From the Journals
Clinical Guidelines

The Most Sensitive Cancer Blood Test Yet

A CRISPR-powered light sensor detected trace amounts of cancer biomarkers in the blood

  • By

  • February 24, 2026

  • 2 min

Share

Researchers have developed an ultra-sensitive blood test that detects trace levels of cancer-related microRNAs, such as miRNA-21 and miRNA-155, which are linked to early tumor development. This groundbreaking technology, published in Optica, utilizes a novel optical sensing system that measures microRNAs at extremely low sub-attomolar concentrations, significantly enhancing early cancer detection. The test showed superior signal detection compared to standard laboratory methods, making it a promising tool for early lung cancer diagnosis and personalized treatment options.

Original Source(s)

The Most Sensitive Cancer Blood Test Yet

A CRISPR-powered light sensor detected trace amounts of cancer biomarkers in the blood

  • February 24, 2026

  • 2 min

Related Content

Baptist Health Miami Cancer Institute Names Bruna Pellini, M.D., Chief of Thoracic Medical Oncology

Board-certified thoracic oncologist Bruna Pellini, M.D., has been named chief of thoracic medical oncology at Baptist Health Miami Cancer Institute.

  • by

  • February 6, 2026

  • 3 min
The Role of Human Leukocyte Antigens in Reducing Lung Cancer Risk

With findings that human leukocyte antigen-II (HLA-II) heterozygosity is associated with reduced risk of developing lung cancer, with particular benefits to smokers, Mount Sinai researchers add evidence to the theory of the immune system's protective function against cancer.

  • by

  • February 5, 2025

  • 1 min
Dana-Farber Research News 9.01.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 through August 15.

  • by

  • September 1, 2024

  • 32 min